Cargando…

Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women

This randomized prospective study aimed to evaluate the clinical outcome of denosumab treatment alone and in combination with teriparatide in treatment-naive postmenopausal Japanese female patients with osteoporosis. Thirty patients were randomly assigned to two groups: (1) denosumab group (denosuma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Yukio, Suzuki, Takako, Kamimura, Mikio, Ikegami, Shota, Murakami, Kohei, Uchiyama, Shigeharu, Taguchi, Akira, Kato, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494185/ https://www.ncbi.nlm.nih.gov/pubmed/28690911 http://dx.doi.org/10.1038/boneres.2016.55

Ejemplares similares

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study
por: Nakamura, Yukio, et al.
Publicado: (2015)

Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment
por: Nakamura, Yukio, et al.
Publicado: (2018)

Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D(3) and alters values of parathyroid hormone, pentosidine, and bone metabolic markers
por: Kamimura, Mikio, et al.
Publicado: (2017)

Efficacy of denosumab therapy for neurofibromatosis type 1 with osteoporosis and history of fractures: a case report
por: Uehara, Masashi, et al.
Publicado: (2018)

Joint Pain Undergoes a Transition in Accordance with Signal Changes of Bones Detected by MRI in Hip Osteoarthritis
por: Kamimura, Mikio, et al.
Publicado: (2013)

Risk factors of adjacent vertebral collapse after percutaneous vertebroplasty for osteoporotic vertebral fracture in postmenopausal women
por: Takahara, Kenji, et al.
Publicado: (2016)

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass
por: Anastasilakis, Athanasios D., et al.
Publicado: (2019)

Associations of self-reported height loss and kyphosis with vertebral fractures in Japanese women 60 years and older: a cross-sectional survey
por: Kamimura, Mikio, et al.
Publicado: (2016)

The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study
por: Park, Chan Ho, et al.
Publicado: (2020)

Anti-Nociceptive Effects of Elcatonin Injection for Postmenopausal Women with Back Pain: A Randomized Controlled Trial
por: Ikegami, Shota, et al.
Publicado: (2010)

A Case with Atypical Clinical Course Diagnosed as Osteoarthritis, Osteonecrosis, Subchondral Insufficiency Fracture, or Rapidly Destructive Coxopathy
por: Nakamura, Yukio, et al.
Publicado: (2014)

The Pathophysiology and Progression of Hip Osteoarthritis Accompanied with Joint Pain are Potentially Due to Bone Alterations - Follow-up Study of Hip OA Patients
por: Kamimura, Mikio, et al.
Publicado: (2014)

The Pathophysiology of Primary Hip Osteoarthritis may Originate from Bone Alterations
por: Kamimura, Mikio, et al.
Publicado: (2013)

Bone alterations are associated with ankle osteoarthritis joint pain
por: Nakamura, Yukio, et al.
Publicado: (2016)

Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate
por: Kamimura, Mikio, et al.
Publicado: (2016)

Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment
por: Giner, Mercè, et al.
Publicado: (2022)

Efficacy of Denosumab for Osteoporosis in Two Patients with Adult-Onset Still’s Disease—Denosumab Efficacy in Osteoporotic Still’s Disease Patients
por: Kumaki, Daiki, et al.
Publicado: (2018)

A case series of pregnancy- and lactation-associated osteoporosis and a review of the literature
por: Nakamura, Yukio, et al.
Publicado: (2015)

Knee Joint Pain Potentially Due to Bone Alterations in a Knee Osteoarthritis Patient
por: Komatsu, Masatoshi, et al.
Publicado: (2014)

Effect of Denosumab and Teriparatide on Fracture Nonunion
por: Boutin, Regine, et al.
Publicado: (2023)

Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
por: Suzuki, Takako, et al.
Publicado: (2017)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
por: Kamimura, Mikio, et al.
Publicado: (2019)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Teriparatide treatment for postmenopausal women with sacral insufficiency fracture
por: Kim, Young-Hoon
Publicado: (2023)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

Comparison in bone turnover markers during early healing of femoral neck fracture and trochanteric fracture in elderly patients
por: Ikegami, Shota, et al.
Publicado: (2009)

Early Changes in Bone Specific Turnover Markers During the Healing Process After Vertebral Fracture
por: Hashidate, Hiroyuki, et al.
Publicado: (2011)

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
por: Mori, Takahiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_46vjbth6o4ppjnv6kl2phked3d